MatthewAgeeMD

Nuclear Medicine • New York, NY

Radiology/Nuclear Medicine, Weill Cornell Imaging - New York Presbyterian Hospital

Join to view full profile

Dr. Agee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Agee's full profile

Already have an account?

Office
525 E 68th St
New York, NY 10065
Phone+1 212-746-6000

Education & Training

Memorial Sloan Kettering Cancer CenterResidency, Nuclear Medicine, 2019 - 2022
Zucker School of Medicine at Hofstra/Northwell at Mather HospitalInternship, Internal Medicine, 2018 - 2019
St. George's University School of MedicineClass of 2018

Certifications & Licensure

NY State Medical License 2022 - 2026
American Board of Nuclear Medicine Nuclear Medicine

Publications & Presentations

PubMed

3 citations
Imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G Aly
The Lancet. Oncology. 2024-08-01
First-in-human imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G Aly
Medrxiv. 2024-01-11
[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.
Jana Ivanidze, Arman Sharbatdaran, Aliah McCalla, Andrew Brandmaier, Eleni Andreopoulou
European Journal of Radiology. 2024-10-15